The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

SWOG-nCartes pilot collaboration shows significant expected time savings for study data entry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The SWOG Cancer Research Network has partnered with cloud clinical research software company nCoup to pilot and deploy the company’s nCartes platform at SWOG sites to help advance data collection. 

In late-phase pilot testing, the results of data entry using the nCartes platform were compared to the current practice of manual data entry, showing significant time savings and improvements in data quality. 

The results were presented at the Society for Clinical Trials 43rd annual meeting.

With nCartes, research sites pull data available in the electronic medical record, such as labs and medications, and automatically transfer the data directly into the research sponsor’s electronic data capture system.

To measure data entry time using the nCartes platform, a study coordinator was timed entering 43 forms. It took 100 minutes to complete all forms, or 2 minutes and 20 seconds per form—a sizable time savings compared to current standard practice. Data quality also improved. 

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
Clinical Roundup

SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer

A new statistical tool that combines multiple clinical and pathologic factors with a patient’s 21-gene Oncotype DX Breast Recurrence Score result provides more accurate estimates about that patient’s breast cancer prognosis and their potential benefit from chemotherapy than either the Recurrence Score result or clinical factors alone, a SWOG Cancer Research study found.
Clinical Roundup

Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study shows

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account